According to TipRanks.com, Friedrichs is ranked #1890 out of 7491 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Qiagen with a $57.92 average price target, implying a 22.2% upside from current levels. In a report released today, Berenberg Bank also maintained a Buy rating on the stock with a EUR56.00 price target.
Qiagen’s market cap is currently $10.85B and has a P/E ratio of 31.70. The company has a Price to Book ratio of -37.51.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.